Title

Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial

Document Type

Journal Article

Publisher

American Society of Clinical Oncology

Place of Publication

United States

Faculty

Computing, Health and Science

School

School of Exercise, Biomedical and health Sciences

RAS ID

10923

Comments

This article was originally published as: Galva, D. A., Taafe, D. R., Spry,N., Joseph, D. Newton, R.U.(2010). Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial. Journal of Clinical Oncology , 28 (2) 340-347. Original article available here

Abstract

Purpose Androgen suppression therapy (AST) results in musculoskeletal toxicity that reduces physical function and quality of life. This study examined the impact of a combined resistance and aerobic exercise program as a countermeasure to these AST-related toxicities. Patients and Methods Between 2007 and 2008, 57 patients with prostate cancer undergoing AST (commenced > 2 months prior) were randomly assigned to a program of resistance and aerobic exercise (n = 29) or usual care (n = 28) for 12 weeks. Primary end points were whole body and regional lean mass. Secondary end points were muscle strength and function, cardiorespiratory capacity, blood biomarkers, and quality of life. Results Analysis of covariance was used to compare outcomes for groups at 12 weeks adjusted for baseline values and potential confounders. Patients undergoing exercise showed an increase in lean mass compared with usual care (total body, P = .047; upper limb, P < .001; lower limb, P = .019) and similarly better muscle strength (P < .01), 6-meter walk time (P = .024), and 6-meter backward walk time (P = .039). Exercise also improved several aspects of quality of life including general health (P = .022) and reduced fatigue (P = .021) and decreased levels of C-reactive protein (P = .008). There were no adverse events during the testing or exercise intervention program.

DOI

10.1200/JCO.2009.23.2488

Access Rights

Free_to_read

 

Link to publisher version (DOI)

10.1200/JCO.2009.23.2488